Apitoria Pharma receives 3 observations from USFDA for Unit-V
Drug Approval

Apitoria Pharma receives 3 observations from USFDA for Unit-V

The company will respond to the US FDA within the stipulated timelines

  • By IPP Bureau | December 12, 2025

The United States Food and Drug Administration (US FDA) inspected Unit-V, an API manufacturing facility, of Apitoria Pharma Private Limited, a wholly owned subsidiary of Aurobindo Pharma, situated at Industrial Development Area, Chemical Zone, Sangareddy, Telangana from December 01 to December 12, 2025.

At the end of the current inspection, a 'Form 483' was issued with 03 observations which are procedural in nature, and the company  will respond to the US FDA within the stipulated timelines.

Other Related stories

Startup

Digitization

India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International